A liquid CGP test that identifies an expanded panel of actionable biomarkers.1,2

Inform treatment selection in patients with advanced-stage cancer, especially those who have progressed on therapy.1,3

References

Results in 10 days.*

Important Note: The Guardant360 test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity testing. This test has not been cleared or approved by the US FDA.

Detects an expanded panel of biomarkers, including bTMB,
MSI status, HRR gene set,
and NTRK fusions.1-4

*10-day turnaround time from sample receipt to results.
bTMB, blood-based tumor mutation burden; CGP, comprehensive genomic profiling; HRR, homologous recombinational repair; MSI, microsatellite instability; NTRK, neurotropic tyrosine receptor kinase.